“…As we alluded to above, emerging evidence had identified that CUL4B was highly expressed in different human malignancies, including carcinoma of the cervix, esophagus, liver, gastric and pancreatic cancer, and had a positive correlation with tumor progression [3,8,12,13,31]. Furthermore, CUL4B overexpression was significantly correlated with tumor size, advanced tumor stage, vascular and lymphatic invasion, distant metastasis, and histological differentiation, and was positively correlated with undesirable outcomes [3,[32][33][34].…”